Home
/
Neuphoria Therapeutics Inc.
/
Financials
/
Quarterly
Neuphoria Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Neuphoria Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Mar 31, 2025
$15.00M
May 20, 2025
Q2
2025
Dec 31, 2024
$662.7K
Feb 17, 2026
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Dec 31, 2025
$1.86M
Feb 17, 2026
Q2
2025
Sep 30, 2025
($9.91M)
Feb 17, 2026
Q1
2025
Sep 30, 2025
($9.91M)
Nov 14, 2025
Q1
2025
Jun 30, 2025
($400.0K)
Nov 14, 2025
Q3
2025
Mar 31, 2025
$11.26M
May 20, 2025
Q3
2025
Dec 31, 2024
($1.94M)
May 20, 2025
Q2
2025
Dec 31, 2024
($1.94M)
Feb 17, 2026
Q1
2025
Sep 30, 2024
($804.8K)
Nov 14, 2025
Q3
2025
Sep 30, 2024
($804.8K)
May 20, 2025
Q2
2025
Sep 30, 2024
($804.8K)
Feb 17, 2026
Q1
2025
Jun 30, 2024
($15.50M)
Nov 14, 2024
Q3
2025
Jun 30, 2024
($15.50M)
May 20, 2025
Q2
2025
Jun 30, 2024
($15.50M)
Feb 14, 2025
Q3
2025
Mar 31, 2024
($2.78M)
May 20, 2025
Q3
2025
Dec 31, 2023
($4.55M)
May 20, 2025
Q2
2025
Dec 31, 2023
($4.55M)
Feb 14, 2025
Q3
2025
Sep 30, 2023
($5.47M)
May 20, 2025
Q2
2025
Sep 30, 2023
($5.47M)
Feb 14, 2025
Q1
2025
Sep 30, 2023
($5.47M)
Nov 14, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Dec 31, 2025
($4.06M)
Feb 17, 2026
Q1
2025
Sep 30, 2025
($5.65M)
Nov 14, 2025
Q3
2025
Mar 31, 2025
$11.98M
May 20, 2025
Q2
2025
Dec 31, 2024
($3.70M)
Feb 17, 2026
Q1
2025
Sep 30, 2024
($3.57M)
Nov 14, 2025
Q3
2025
Mar 31, 2024
($2.39M)
May 20, 2025
Q2
2025
Dec 31, 2023
($4.55M)
Feb 14, 2025
Q1
2025
Sep 30, 2023
($5.47M)
Nov 14, 2024